ES2339846T3 - Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob. - Google Patents

Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob. Download PDF

Info

Publication number
ES2339846T3
ES2339846T3 ES02011474T ES02011474T ES2339846T3 ES 2339846 T3 ES2339846 T3 ES 2339846T3 ES 02011474 T ES02011474 T ES 02011474T ES 02011474 T ES02011474 T ES 02011474T ES 2339846 T3 ES2339846 T3 ES 2339846T3
Authority
ES
Spain
Prior art keywords
protein
amino acids
amino acid
increase
mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02011474T
Other languages
English (en)
Spanish (es)
Inventor
Mary Ann Pelleymounter
Christopher Francis Toombs
Michael Benjamin Mann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2339846T3 publication Critical patent/ES2339846T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES02011474T 1995-11-22 1996-11-04 Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob. Expired - Lifetime ES2339846T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22
US561732 1995-11-22

Publications (1)

Publication Number Publication Date
ES2339846T3 true ES2339846T3 (es) 2010-05-26

Family

ID=24243198

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02011474T Expired - Lifetime ES2339846T3 (es) 1995-11-22 1996-11-04 Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob.
ES96938773T Expired - Lifetime ES2217327T3 (es) 1995-11-22 1996-11-04 Proteina ob para aumentar la masa de tejido magro.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES96938773T Expired - Lifetime ES2217327T3 (es) 1995-11-22 1996-11-04 Proteina ob para aumentar la masa de tejido magro.

Country Status (15)

Country Link
EP (3) EP0956862A1 (cg-RX-API-DMAC7.html)
JP (2) JP4173914B2 (cg-RX-API-DMAC7.html)
AT (2) ATE259243T1 (cg-RX-API-DMAC7.html)
AU (3) AU7607496A (cg-RX-API-DMAC7.html)
CA (2) CA2358862A1 (cg-RX-API-DMAC7.html)
DE (2) DE69638119D1 (cg-RX-API-DMAC7.html)
DK (1) DK0866720T3 (cg-RX-API-DMAC7.html)
ES (2) ES2339846T3 (cg-RX-API-DMAC7.html)
IL (2) IL124442A0 (cg-RX-API-DMAC7.html)
MX (1) MX9803992A (cg-RX-API-DMAC7.html)
NZ (3) NZ512083A (cg-RX-API-DMAC7.html)
PT (1) PT866720E (cg-RX-API-DMAC7.html)
SI (1) SI0866720T1 (cg-RX-API-DMAC7.html)
WO (1) WO1997018833A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA969605B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
NZ512083A (en) * 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
JP2000505791A (ja) * 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
EP0917469A1 (en) * 1996-04-19 1999-05-26 ZymoGenetics, Inc. Methods for inducing bone formation
RS49927B (sr) * 1996-12-20 2008-09-29 Amgen Inc., Preparati ob fuzionog proteina i postupci
CA2274799A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (en) * 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
AU3863699A (en) * 1998-04-20 1999-11-08 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2000024418A1 (en) * 1998-10-27 2000-05-04 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
PT1151102E (pt) * 1999-02-12 2006-07-31 Amgen Inc Composicoes de leptina glicosilada e metodos afins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
PT2219031E (pt) 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
WO2006005058A2 (en) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
DK1814590T4 (da) 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
WO2008048691A2 (en) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
BR112013007385B1 (pt) 2010-09-28 2022-07-26 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
AU2013323528B2 (en) 2012-09-27 2016-11-10 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
HUE042196T2 (hu) 2013-11-26 2019-06-28 Childrens Medical Ct Corp Vegyületek elhízás kezelésére és alkalmazási eljárásaik
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
DK3509624T3 (da) 2016-09-12 2023-11-13 Amryt Pharmaceuticals Inc Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
AU7535394A (en) * 1993-08-13 1995-03-14 Putzmeister-Werk Maschinenfabrik Gmbh Process and device for treating the surface of large objects
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
NZ512083A (en) * 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
CZ9802013A3 (cs) * 1995-12-27 1998-09-16 Genentech, Inc. Deriváty OB proteinu, chimerní OB polypeptidy, prostředky pro léčbu obezity a dalších fyziologických stavů a způsob léčení těmito prostředky, kódující sekvence pro OB protein, expresní vektor nesoucí tuto sekvenci, buňky transformované tímto vektorem a způsob jejich kultivace, a způsob navození růstu buněk s pomocí OB proteinu
RS49927B (sr) * 1996-12-20 2008-09-29 Amgen Inc., Preparati ob fuzionog proteina i postupci
CN1202862C (zh) * 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法

Also Published As

Publication number Publication date
SI0866720T1 (en) 2004-10-31
ATE455554T1 (de) 2010-02-15
DK0866720T3 (da) 2004-06-14
EP0866720A1 (en) 1998-09-30
CA2236163A1 (en) 1997-05-29
DE69631544D1 (de) 2004-03-18
IL124442A0 (en) 1998-12-06
ES2217327T3 (es) 2004-11-01
DE69638119D1 (de) 2010-03-11
PT866720E (pt) 2004-06-30
AU763769B2 (en) 2003-07-31
IL127926A (en) 2006-08-20
MX9803992A (es) 1998-09-30
IL127926A0 (en) 1999-11-30
JP4173914B2 (ja) 2008-10-29
NZ512083A (en) 2003-02-28
EP1285664A3 (en) 2003-07-30
JP2000500492A (ja) 2000-01-18
JP4227325B2 (ja) 2009-02-18
ATE259243T1 (de) 2004-02-15
ZA969605B (en) 1997-06-02
AU4265200A (en) 2000-09-21
AU763755B2 (en) 2003-07-31
EP0866720B1 (en) 2004-02-11
EP1285664A2 (en) 2003-02-26
AU4265300A (en) 2000-09-07
JP2002206000A (ja) 2002-07-23
EP1285664B1 (en) 2010-01-20
CA2358862A1 (en) 1997-05-29
EP0956862A1 (en) 1999-11-17
WO1997018833A1 (en) 1997-05-29
DE69631544T2 (de) 2004-12-23
NZ527007A (en) 2005-01-28
AU7607496A (en) 1997-06-11
NZ511617A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
ES2339846T3 (es) Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob.
JP4173913B2 (ja) Ｏｂタンパク質組成物を用いて血中脂質レベルを減少させ又は減少した血中脂質レベルを維持する方法
Gualandi-Signorini et al. Insulin formulations-a review
US7718400B2 (en) Methods of increasing lean tissue mass using OB protein compositions
JP2004527487A (ja) 真性糖尿病の治療方法
EP0515434B1 (en) Method for treating intestinal diseases
US20090298758A1 (en) Thymosin beta 4 derivatives and use thereof
CN101969979A (zh) 含有脱辅基水母蛋白的组合物及其使用方法
KR20010006392A (ko) 안정한 활성 인체 ｏｂ 단백질 및 항체 ｆｃ 사슬 복합체를 함유하는 조성물 및 방법
JP3034032B2 (ja) 腸疾患用薬剤
TW492869B (en) Use of GIP-1 or analogs to abolish catabolic changes after surgery
AU2006201747B2 (en) Methods of Increasing Lean Tissue Mass Using OB Protein Compositions
AU2004200516B2 (en) Methods of Increasing Lean Tissue Mass Using OB Protein Compositions
AU2003201360B2 (en) Methods of Reducing or Maintaining Reduced Levels of Blood Lipids Using OB Protein Compositions
HK1022438A (en) Methods of increasing lean tissue mass using ob protein compositions
AU7226291A (en) Method for treating intestinal diseases
MXPA99001871A (en) Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery